丝聚蛋白功能缺失与胸腺基质淋巴细胞生成素变异和儿童特应性皮炎治疗使用的关联
这项前瞻性队列研究纳入842名儿童特应性皮炎患者,随访平均7.6年,评估FLG和TSLP基因型与治疗使用的关系。携带2个FLG功能缺失等位基因者皮肤清除可能性更低(OR 0.20)且更可能使用激素(OR 5.04);TSLP rs1898671纯合子外用钙调神经磷酸酶抑制剂使用更少(OR 0.16)。
要点
- 2个FLG功能缺失等位基因与更低皮肤清除率和更高激素使用相关。
- TSLP rs1898671纯合子外用钙调神经磷酸酶抑制剂使用更少。
- 野生型与杂合子患者多数结局无显著差异。
核心结论
- 治疗使用和可能的疗效与遗传变异相关。
- 差异主要见于2个FLG功能缺失等位基因或TSLP rs1898671纯合子儿童。
- 多数结局中野生型与杂合子患者无显著差异。
研究设计与样本
- 前瞻性队列研究,纳入842名2至17岁特应性皮炎儿童,随访平均7.6年(约6396人年)。
- 138名患者(16.4%)在10年随访中无缺失数据。
主要发现
- 2个FLG功能缺失等位基因患者报告皮肤清除的可能性更低(OR 0.20;95% CI 0.07-0.55)。
- 2个FLG功能缺失等位基因患者使用激素的可能性更高(OR 5.04;95% CI 1.91-13.31)。
- TSLP rs1898671纯合子报告外用钙调神经磷酸酶抑制剂使用的可能性更低(OR 0.16;95% CI 0.06-0.42)。
- 停用外用钙调神经磷酸酶抑制剂的患者中,rs1898671单核苷酸多态性者更可能停用所有其他治疗(OR 0.45;95% CI 0.26-0.76)。
临床怎么用
- 基因型信息可能有助于识别治疗需求更高的儿童特应性皮炎患者。
- 关注FLG功能缺失等位基因数量和TSLP rs1898671状态而非单纯有无变异。
局限性
- 仅16.4%患者有10年完整随访数据。
- 治疗使用为自报结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Atopic dermatitis (AD) is a common illness of childhood. OBJECTIVE: To determine whether variations in FLG and TSLP genotype corresponded to differences in treatment use over time. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study recruited and followed a volunteer sample of 842 children enrolled in the Pediatric Eczema Elective Registry who provided saliva samples for DNA extraction for 10 years. Eligibility criteria included age 2 to 17 years, AD diagnosis without cancer, and prior pimecrolimus use. Participants were followed for an average of 7.6 years (approximately 6396 person-years); 138 patients (16.4%) had no missing data over 10 years of follow-up. EXPOSURES: Evaluation of FLG and TSLP genotypes. MAIN OUTCOMES AND MEASURES: Self-reported outcomes of whether a child's AD required the use of topical steroids, topical calcineurin inhibitors, or other medications within the past 6 months at 6-month intervals. RESULTS: Overall, 842 children (mean [SD] age, 1.9 [2.7] years; 438 girls) were included in this study. Treatment use among patients with 0, 1, or 2 FLG loss of function (LOF) alleles was compared as well as those that were wildtype, heterozygous, or homozygous for the TSLPrs1898671 single-nucleotide polymorphism. Patients with 2 FLG LOF alleles were less likely to report skin clearance (odds ratio [OR], 0.20; 95% CI, 0.07-0.55) and more likely to use steroids (OR, 5.04; 95% CI, 1.91-13.31). TSLPrs1898671 homozygotes were less likely to report topical calcineurin inhibitor use (OR, 0.16; 95% CI, 0.06-0.42), and among all patients that had discontinued topical calcineurin inhibitors, those with the rs1898671 single-nucleotide polymorphism were more likely to have stopped all other treatment as well (OR, 0.45; 95% CI, 0.26-0.76). In all but 1 of our comparisons, no significant difference between wildtype and heterozygous patients were found. CONCLUSIONS AND RELEVANCE: Treatment use and likely effectiveness was associated with genetic variation. Variation was limited to children with 2 FLG LOF alleles or TSLPrs1898671 homozygotes, with no significant difference observed between wildtype and heterozygous patients in the majority of the outcomes studied. Therefore, the key differentiating factor in our analyses was the number of FLG LOF alleles or TSLP SNPs rather than the absolute presence or absence of these variants. This may be an important consideration for future studies.
引用
- Chang J, Mitra N, Hoffstad O, et al. Association of Filaggrin Loss of Function and Thymic Stromal Lymphopoietin Variation With Treatment Use in Pediatric Atopic Dermatitis. JAMA Dermatol. 2017. PMID: 27902816. doi:10.1001/jamadermatol.2016.4467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。